As far as biotech he weould have said the same about celg or Amgn in its early days. I have done enough research to do this is cut from the same ilk. And so did those back in December who bought the secondary at no discoun to market (at RETAIL) unheard of price. Yes, he has a point. But the point but be made and refined, separated by company. The moment he says any small biotech SELL SELL SELL he should be taken to task company by company he mentions the next day, by someone a bit less bafoon -ish or theatrics inclined. Simply, he is mistaken.